テンペスト・セラピューティクスに関するコメント

$テンペスト・セラピューティクス (TPST.US)$ Hey good morning guys and gals. I am definitely 100% on board with this I believe it has a lot of potential but but but but. Keep in mind it's got a reverse split coming for 1/2 or 1/15 I sold half to have plenty of ammunition to buy in when it dips. I'm looking for ¢ .70 or under.  I don't see this is a bad thing. NFA Just my two pennies worth.

$テンペスト・セラピューティクス (TPST.US)$ if you would like to gamble on this kind of growth company, you must be well prepared for the dip and loss or holding for the long term. Complaining doesn't help.

$テンペスト・セラピューティクス (TPST.US)$
13/11/2024 - 05:21
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCC
Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial
Received final funding approval from NCI to move TPST-1495 into a Phas...

$テンペスト・セラピューティクス (TPST.US)$
12/11/2024 - 21:00
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a “Study May Proceed” letter fro...

$テンペスト・セラピューティクス (TPST.US)$ be patience 要有耐心

$テンペスト・セラピューティクス (TPST.US)$ Reuters· just
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

$テンペスト・セラピューティクス (TPST.US)$ come on baby booom

$テンペスト・セラピューティクス (TPST.US)$ oh shiiiiii